Summary (tl;dr)

Former President Donald Trump has signed an executive order directing federal agencies to expedite the reclassification of marijuana from a Schedule I to a Schedule III controlled substance, a move poised to significantly impact medical research and the cannabis industry.

Essential Background

In the United States, drugs are classified into five "schedules" under the Controlled Substances Act (CSA) based on their potential for abuse, accepted medical use, and potential for dependence. Schedule I drugs, such as heroin, LSD, and cannabis, are considered to have a high potential for abuse and no currently accepted medical use. In contrast, Schedule III drugs, which include substances like ketamine, anabolic steroids, and Tylenol with codeine, have a moderate to low potential for physical and psychological dependence and an accepted medical use. The reclassification process was initiated by the Biden administration in October 2022, and in August 2023, the U.S. Department of Health and Human Services (HHS) formally recommended that the Drug Enforcement Administration (DEA) move marijuana to Schedule III, citing credible scientific support for its medical use. The DEA then proposed a rule in May 2024 to transfer marijuana to Schedule III, but the formal rulemaking process, including administrative hearings, had been stalled.

The Full Story

On December 18, 2025, former President Donald Trump signed an executive order from the Oval Office to expedite the reclassification of marijuana. This order directs the Attorney General to take all necessary steps to complete the rulemaking process for moving marijuana from Schedule I to Schedule III under the CSA in the most expeditious manner. President Trump emphasized that this action responds to calls from many Americans, particularly those suffering from various medical conditions, and aims to facilitate medical research. While this executive order signals a significant shift in federal drug policy, it does not federally legalize marijuana for recreational use. Instead, it aims to accelerate a process that was previously in a holding pattern, allowing for a quicker transition to a less restrictive schedule.

Why It Matters

This reclassification is significant for several reasons. Moving marijuana to Schedule III would ease barriers to medical research, allowing scientists to more easily study its benefits, potential dangers, and future treatments. For the state-legal cannabis industry, it could alleviate the substantial federal tax burden imposed by Section 280E of the IRS code, which currently prevents businesses dealing with Schedule I or II substances from taking ordinary business deductions. This change could also improve access to banking and financial services for cannabis businesses and attract new investment, potentially transforming the $32 billion industry. Furthermore, it validates the long-held belief by many patients and physicians that cannabis possesses legitimate medical utility. Despite the reclassification, marijuana would remain a federally controlled substance, and its interstate commerce would still be prohibited, leaving federal recreational prohibitions in place.

Geographic Location

• Oval Office, White House, Washington, D.C., District of Columbia, United States (President Donald Trump signed an executive order to expedite marijuana reclassification)